Sep 14, 2026 08:31AM
Sep 14, 2026 08:30AM
Aug 11, 2026 04:10PM
Jul 15, 2026 08:00AM
Jul 15, 2026 08:00AM
Jun 2, 2026 09:06AM
Jun 2, 2026 09:06AM Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
May 21, 2026 05:00PM
May 21, 2026 05:00PM
May 14, 2026 04:10PM
Apr 21, 2026 10:00AM
Apr 21, 2026 10:00AM
Apr 17, 2026 04:01PM
Apr 17, 2026 04:01PM Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting
Apr 9, 2026 04:01PM
Apr 9, 2026 04:01PM
Mar 26, 2026 06:49AM
Feb 24, 2026 04:30PM
Jan 28, 2026 06:45AM
Jan 27, 2026 07:05AM
Jan 27, 2026 07:05AM Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC
Jan 27, 2026 07:00AM
Jan 27, 2026 07:00AM
Dec 21, 2025 04:00AM
Dec 12, 2025 10:31AM
Dec 8, 2025 04:06PM
Dec 8, 2025 04:05PM
Nov 6, 2025 04:05PM Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update
Jul 29, 2025 04:07PM
Jul 29, 2025 04:07PM
Jul 29, 2025 04:05PM
Jul 8, 2025 08:50AM
Jun 17, 2025 04:05PM
Jun 17, 2025 04:05PM
Jun 2, 2025 04:06PM Cardiff Oncology (CRDF) Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel
Jun 2, 2025 04:05PM
May 8, 2025 04:05PM
Apr 23, 2025 04:09PM
Apr 23, 2025 04:05PM
Apr 15, 2025 04:05PM
Apr 14, 2025 06:41AM
Feb 27, 2025 04:05PM Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
Jan 2, 2025 12:51PM
Dec 26, 2024 09:00AM
Dec 10, 2024 07:21AM
Dec 10, 2024 07:20AM
Dec 10, 2024 07:12AM
Dec 10, 2024 06:00AM
Nov 19, 2024 08:04AM Cardiff Oncology (CRDF) Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC
Nov 19, 2024 08:00AM

334,271 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All